4D pharma plc (AIM: DDDD, Nasdaq: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, provides an update
REGULATED INFORMATION Preliminary documents for the Extraordinary General Meeting have been made available on company’s website Mont-Saint-Guibert, Belgium, 13 June 2022, 7am CEST. | June 13, 2022